ET
Eton Pharmaceuticals, Inc.
ETON · NASDAQ
$57.68 -4.53% (-$2.74)
1M -4.57%
Market Cap $1.58B
P/E Ratio 124.53x
Div. Yield -
ROE 40.13%
Bulios Fair Price
$34.26
40.6% downside
Current Price
$57.68
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ETON is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Strong
7/9Valuation
0 /100
Expensive P/E 124.53x
EV/EBITDA 85.23x
P/S 14.96x
Growth
100 /100
Growing Rev. growth 55.53%
FCF growth 71.14%
Book val. growth 25.99%
Profitability
79 /100
Strong Gross margin 57.87%
Net margin 12.02%
Op. margin 15.44%
Quality
95 /100
Excellent ROIC 20.41%
ROE 40.13%
ROA 10.96%
Debt
81 /100
Low Debt/Equity 0.62x
Current ratio 1.52x
Int. coverage 5.80x
Stability
26 /100
Unstable Beta 0.90x
Rev. volatility 41.76%
EPS volatility 208.12%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ETON
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Sean E. Brynjelsen
Employees
44
Headquarters
Deer Park
Upcoming events
05 NOV
Earnings
Upcoming earnings report